Enjoy complimentary customisation on priority with our Enterprise License!
The microbial products market share is expected to increase by USD 18.41 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 12.20%. This microbial products market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The microbial products market report also offers information on several market vendors, including bioMerieux SA, GlaxoSmithKline Plc, Kyowa Hakko Bio Co. Ltd., Merck KGaA, NovaMedica, Novartis AG, Pfizer Inc., Sanofi SA, Thermo Fisher Scientific Inc., and Valent BioSciences LLC among others. Furthermore, this report extensively covers microbial products market segmentation by application (pharmaceutical, diagnostics, and biotechnology) and geography (North America, Europe, Asia, and ROW).
Download the Free Report Sample to Unlock the Microbial Products Market Size for the Forecast Period and Other Important Statistics
"With the growing need to counter the rising prevalence of microbial diseases and healthcare burden, the demand for microbial-based therapeutic and diagnostic products is increasing in the US and Canada. Diseases such as diabetes, IBD, C. difficile infections, and cancer are prominently contributing to the growing healthcare expenditure, which is a major concern for the governments across these countries."
The high demand for microbial products in the pharmaceutical industry is notably driving the microbial products market growth, although factors such as challenges related to manufacturing and formulation may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the microbial products industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Microbial Products Market Driver
One of the key factors driving growth in the microbial products market is the high demand for microbial products in the pharmaceutical industry. Microbiology has immense potential in the pharmaceutical industry. The exploitation of microorganisms and the development of microbes-based products play a prominent role in the manufacturing of vaccines, antibiotics, insulin, and steroids. Vaccines are made from killed or weakened microorganisms, their toxins, or their surface proteins. The growing focus on research for the development of new antibiotic substances is increasing the approval of new antibiotics by regulatory authorities, such as the US FDA and EMA, which is driving the demand for microbial products among pharmaceutical research laboratories. The vast applications of microbial products in the pharmaceutical industry are expected to propel the growth of the global microbial products market.
Key Microbial Products Market Challenge
The difficulties related to the manufacturing and formulation will be a major challenge for the microbial products market during the forecast period. Microbial product manufacturers often come across challenging situations during clinical developments, manufacturing, and technology considerations. Producing stable engraftments, discovering relevant biosensors, producing robust gene circuits, maintaining safety and bio-contentment standards, and efficient designing of microbial therapies are some of the challenges faced by vendors during manufacturing and formulation operations. Resolving such issues during routine operations slows the development of microbial products, creating hurdles in the swift growth of the global microbial products market.
This microbial products market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
The parent, global life science tools and services market covers products and companies engaged in R&D of a variety of product categories, including capital equipment, instruments, accessories, and consumables that are used for R&D on pharmaceuticals and biotechnology products and laboratory diagnosis of various diseases.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the microbial products market encompasses successful business strategies deployed by the key vendors. The microbial products market is fragmented and the vendors are deploying growth strategies such as forming strategic partnerships to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The microbial products market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
For more insights on the market share of various regions Request for a FREE sample now!
41% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for microbial products in North America. However, the market growth rate in this region will be slower than the growth of the market in the European and Asian regions.
The increasing focus on microbe-based clinical research and the growing prevalence of new infectious diseases will facilitate the microbial products market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
To gain further insights on the market contribution of various segments Request for a FREE sample
The microbial products market share growth by the pharmaceutical segment will be significant during the forecast period. The pharmaceutical segment is growing with the rise in the number of pharmaceutical companies to meet the increased demand for novel drugs. This is due to the rising prevalence of rare diseases such as neonatal herpes and diphtheria. The growth of the pharmaceutical industry will be mainly driven by market expansion in developing countries due to the low labor and manufacturing costs.
This report provides an accurate prediction of the contribution of all the segments to the growth of the microbial products market size and actionable market insights on post COVID-19 impact on each segment.
Microbial Products Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 12.20% |
Market growth 2022-2026 |
$ 18.41 billion |
Market structure |
Fragmented |
YoY growth (%) |
11.07 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 41% |
Key consumer countries |
US, Canada, China, Germany, and UK |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
bioMerieux SA, GlaxoSmithKline Plc, Kyowa Hakko Bio Co. Ltd., Merck KGaA, NovaMedica, Novartis AG, Pfizer Inc., Sanofi SA, Thermo Fisher Scientific Inc., and Valent BioSciences LLC |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Application
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.